These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 6462106)

  • 41. Effect of 6059-S, a noval oxacephem, on cross-linking reaction of peptidoglycan biosynthesis in Escherichia coli, Pseudomonas aeruginosa and Serratia marcescens.
    Takata N; Ogawa M; Kosaki G; Suginaka H
    Arch Microbiol; 1981 Sep; 130(1):90-1. PubMed ID: 6458255
    [No Abstract]   [Full Text] [Related]  

  • 42. Effect of 7 alpha substitution of cephems on their beta-lactamase stability and affinity for penicillin-binding proteins in Morganella morganii.
    Ohya S; Yamazaki M; Sugawara S
    Antimicrob Agents Chemother; 1983 Apr; 23(4):522-5. PubMed ID: 6602587
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Correlation of susceptibility and resistance of twenty-five bacterial strains by analysis of MIC database of cephalosporins and oxacephalosporins.
    Kodama Y; Inouye S
    J Antibiot (Tokyo); 1997 Mar; 50(3):246-55. PubMed ID: 9127196
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Moxalactam and cefotaxime--two new beta-lactam antibiotics compared with three well-known cephalosporins].
    Baumgärtner M; Dickgiesser N; Müller S; Wundt W
    Arzneimittelforschung; 1981; 31(10):1677-81. PubMed ID: 6274361
    [TBL] [Abstract][Full Text] [Related]  

  • 45. New drug evaluations: moxalactam (Moxam, Eli Lilly).
    Polk RE
    Drug Intell Clin Pharm; 1982 Feb; 16(2):104-12. PubMed ID: 6210519
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cefotetan activity against Gram-negative aerobes and anaerobes.
    Moosdeen F; Maskell J; Philpott-Howard J; Williams JD
    J Antimicrob Chemother; 1983 Jan; 11 Suppl():59-65. PubMed ID: 6601657
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The activity in vitro of ceftazidime (GR 20263) and moxalactam (LY 127935) against Gram-negative bacteria from hospital patients.
    Pedler SJ
    J Antimicrob Chemother; 1981 Nov; 8(5):417-20. PubMed ID: 6459317
    [No Abstract]   [Full Text] [Related]  

  • 48. In vitro activity of moxalactam against pathogenic bacteria and its comparison with other antibiotics.
    Perrymann F; Flournoy DJ; Qadri SM
    Chemotherapy; 1983; 29(1):37-42. PubMed ID: 6219865
    [TBL] [Abstract][Full Text] [Related]  

  • 49. In vitro activity of moxalactam alone and in combination with penicillin against common meningeal pathogens.
    Azimi PH; Dunphy MG
    Antimicrob Agents Chemother; 1982 Mar; 21(3):521-4. PubMed ID: 6213193
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparison of cefotaxime and moxalactam pharmacokinetics and tissue levels.
    Wise R; Baker S; Livingston R
    Antimicrob Agents Chemother; 1980 Sep; 18(3):369-71. PubMed ID: 6252833
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Timed bacteriostatic and bactericidal activities of latamoxef against clinical strains of gram-negative bacteria].
    Masuda G; Negishi M; Young C; Mukaiyama T; Hanai N; Uchikawa S; Thoma T; Yamazaki E
    Jpn J Antibiot; 1983 Jan; 36(1):16-21. PubMed ID: 6221128
    [No Abstract]   [Full Text] [Related]  

  • 52. The bacterial outer-membrane permeability of beta-lactam antibiotics.
    Sawai T; Matsuba K; Tamura A; Yamagishi S
    J Antibiot (Tokyo); 1979 Jan; 32(1):59-65. PubMed ID: 368002
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Antibacterial activity of N-formimidoyl thienamycin in comparison with cefotaxime, lamoxactam, cefoperazone, piperacillin gentamicin.
    Braveny I; Machka K; Elsser R
    Infection; 1982 Jan; 10(1):45-9. PubMed ID: 6279523
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Quality control of moxalactam susceptibility disks.
    Barry AL; Preston DA; Jones RN; Gavan TL; Thornsberry C
    J Clin Microbiol; 1983 Jun; 17(6):1032-8. PubMed ID: 6223936
    [TBL] [Abstract][Full Text] [Related]  

  • 55. In vitro activities of moxalactam and cefotaxime against aerobic gram-negative bacilli.
    Jorgensen JH; Crawford SA; Alexander GA
    Antimicrob Agents Chemother; 1980 Jun; 17(6):937-42. PubMed ID: 6250470
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparison of cefoperazone, cefotaxime, and moxalactam (LY127935) against aerobic gram-negative bacilli.
    Lang SD; Edwards DJ; Durack DT
    Antimicrob Agents Chemother; 1980 Mar; 17(3):488-93. PubMed ID: 6252831
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Correlation of moxalactam (LY127935) susceptibility tests by disk diffusion and agar plate dilution methods.
    Hall WH; Opfer BJ
    Antimicrob Agents Chemother; 1981 Jan; 19(1):130-3. PubMed ID: 6454380
    [TBL] [Abstract][Full Text] [Related]  

  • 58. In-vitro activity and beta-lactamase stability of Sch 29482, a penem antibiotic. Comparisons with ceftazidime and moxalactam.
    Dornbusch K; Adamsson L; Gezelius L; Hallander H
    J Antimicrob Chemother; 1982 Feb; 9 Suppl C():113-21. PubMed ID: 6460739
    [No Abstract]   [Full Text] [Related]  

  • 59. Antimicrobial activity, beta-lactamase stability and beta-lactamase inhibition of cefotetan and other 7-alpha-methoxy beta-lactam antimicrobials.
    Jones RN; Wilson HW
    Diagn Microbiol Infect Dis; 1983 Mar; 1(1):71-83. PubMed ID: 6323095
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Synthesis and antibacterial activity of 1-oxacephem derivatives.
    Narisada M; Yoshida T; Onoue H; Ohtani M; Okada T; Nagata W
    J Antibiot (Tokyo); 1982 Apr; 35(4):463-82. PubMed ID: 6212566
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.